Sexual dysfunction is common among patients with major depressive disorder (MDD). In the CLARITY study, the safety and efficacy of adjunctive pimavanserin, an inverse agonist at 5‐HT_2A receptors, were demonstrated when added to existing treatment for MDD. This analysis provides a detailed assessment of the effects of pimavanserin on sexual function from the CLARITY study.

中文翻译：

---

辅助皮万古林治疗MDD期间性功能的改善：次要分析。

重度抑郁症（MDD）患者常见性功能障碍。在CLARITY研究中，在现有的MDD治疗药物中加入了辅助的pimavanserin（5-HT _2A受体反向激动剂）的安全性和有效性。这项分析通过CLARITY研究提供了对匹马西林对性功能的影响的详细评估。